Welcome to our dedicated page for Bioadaptives news (Ticker: BDPT), a resource for investors and traders seeking the latest updates and insights on Bioadaptives stock.
Bioadaptives Inc. (BDPT) delivers science-driven nutraceutical innovations through rigorous research and clinical validation. This news hub provides investors and industry observers with essential updates on product developments, research milestones, and strategic initiatives shaping the future of evidence-based wellness solutions.
Access official press releases and curated analysis covering clinical trial progress, intellectual property advancements, and market expansion efforts. Our repository simplifies tracking of regulatory updates, partnership announcements, and scientific breakthroughs in cognitive health, anti-aging formulations, and bioavailability enhancement technologies.
Key updates include R&D investment disclosures, human trial phase completions, and educational outreach programs. Bookmark this page for structured access to material events affecting Bioadaptives' position in the competitive nutraceutical sector, with all content vetted for relevance to long-term company strategy.
BioAdaptives, Inc. (BDPT) announces a new program aimed at helping seniors afford their advanced nutraceutical supplements amidst rising inflation. The initiative offers discounts for single-container purchases, reducing prices from $59.95-$69.95 to $29.95-$39.95. This strategy is expected to tap into the growing nutraceutical market, projected to reach USD 454.55 billion by 2030, with a CAGR of 9.0%. CEO Edward Jacobs emphasized the importance of making health-related products accessible for seniors, particularly in light of COVID-related health issues and rising living costs.
BioAdaptives, Inc. (OTCMkts: BDPT) announced positive results from a study led by Dr. Lorrin Koran at Stanford Medical School on Pluripain® for Gadolinium Deposition Disease (GDD). The study revealed that 60% of participants experienced significant relief from pain and brain fog. Pluripain® is suggested to reduce opioid dependency in patients. The CEO of BioAdaptives expressed optimism about further studies confirming the supplement's benefits. GDD arises from excessive gadolinium build-up from MRIs, affecting certain patients.
BioAdaptives, Inc. (OTCMkts: BDPT) has acquired U.S. Patent 9,783,432B from inventor Thomas J. Mohr to enhance oxygen capacity in water. This technology embeds oxygen molecules, offering long-term aerobic benefits for performance and health. The company is forming MORO2, Inc. to develop consumer products based on this technology, with marketing set to begin in 2Q 2022. Under the agreement, BioAdaptives holds exclusive rights for two years and has engaged Mohr as a consultant. This acquisition positions the company for growth in nutraceutical-enhanced oxygenated water products.
BioAdaptives, Inc. (OTCMkts: BDPT) has initiated a study of its Lung Armor™ package, which includes the Lung Cleanser™ device and PrimiLungs™ supplement, targeting respiratory health in long-term smokers and those exposed to second-hand smoke. The Lung Cleanser™ is an FDA-cleared medical device aimed at enhancing lung clearance. Research will evaluate user experience and potential improvements in product efficacy, with initial studies planned in the US and possibly Eastern Europe. The company seeks to provide daily support for smokers’ breathing and health through its innovative products.
BioAdaptives (OTCMkts: BDPT) announced a Letter of Intent to acquire U.S. Patent 9,783,432B from inventor Thomas J. Mohr. This patent covers a revolutionary technology that enhances water's ability to retain oxygen, providing longer-term health benefits compared to traditional oxygenated water. CEO Edward Jacobs emphasized the potential advantages of the new product, which may improve endurance and overall wellness. While the financial terms are still being negotiated, the deal involves cash, royalties, and warrants. BioAdaptives aims to expand its product line with this innovative technology.
BioAdaptives (OTC: BDPT) has entered a Marketing Agreement with Acoustic Innovations LLC for the LungFlute™ device, which is FDA-cleared and supports lung health and diagnosis of pulmonary diseases. The agreement grants BioAdaptives marketing rights across the US, Canada, and other approved regions. The LungFlute™ aids in mucus clearance and is expected to enhance TB diagnosis in an $800,000 trial in Africa. BioAdaptives plans to promote the device alongside its PrimiLungs™ supplement in a new package called LungArmor™ aimed at improving lung hygiene and immune defense.
BioAdaptives, Inc. (OTCMkts: BDPT) announces a collaboration with Professor Lorrin Koran from Stanford Medical Center for research on PluriPain®, aimed at alleviating chronic pain linked to Gadolinium Deposition Disease. This rare disorder surfaces in patients exposed to gadolinium from MRI contrast agents, resulting in prolonged pain through inflammatory cytokine production. BioAdaptives will supply PluriPain® for this research, furthering its commitment to addressing inflammatory pain issues.
BioAdaptives (OTCMkts: BDPT) announced the launch of its Ambassador Program for the Livestock Impact Division, promoting products like Equine All-in-One™ and Canine Regen®. The program aims to enhance affiliate marketing through social media and discounts, targeting industry participants. Notably, Equine All-in-One™ is a plant-based supplement reported to improve horse health and performance, while Canine Regen® supports dog health and regeneration. The initiative will be led by COO Charles Townsend, with plans for national and potential international outreach.
